Kim Walpole

I think, you know, this is an interesting space to be in right now.

Clinical trials is a really hot conversation.

And so a couple of years ago when we initially started thinking about raising, there was definitely this sense of, you know, AI in clinical trials, like clinical trials isn't hot as it is.

You're trying to apply AI, you know, we're not sure about that.

And so it was really interesting for us going through that process and going, okay, maybe we'll wait until, you know, the, the,

there's a better climate.

And I think right now really is, we've got a lot of interest from investors right now.

We're really just looking to lock in our lead.

But in terms of just all around interest, we've got emails coming in, calls, let's talk.

So pretty exciting.

The conversations we're having is at a 10 million pre.

So what our revenue is, you know, currently we're at about 25K MRR.

Oh, gosh.

We weren't, we didn't even have, we were pre-revenue at that time.

You know, we had some folks that, like I said, had given us some money that they were putting towards it, but it wasn't, it definitely wasn't, we weren't counting it as pre-revenue at that time.

Well, that's a good question.

I mean, I think, again, coming back to where we are in the space, the way that the space is moving so quickly, and people are really excited about this particular approach.

Now, when we talk about our pipeline, so there's a conversation around, okay, what are we generating right now?

But then if you look at our sales pipeline, we've got

seven trials from one customer that is coming up, another five trials.